Evidence map›Paper›PMID 34625019›Full record

ArticleThe journal of headache and pain2021

Inflammatory complications of CGRP monoclonal antibodies: a case series.

Jason C Ray, Penelope Allen, Ann Bacsi, Julian J Bosco, Luke Chen, Michael Eller, Hock Kua, Lyndell L Lim, Manjit S Matharu, Mastura Monif and 3 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of headache and pain, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Macrophages hit a nerve in painful joint venture.Nature reviews. Rheumatology · 2025
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Jason C RayDepartment of Neurology, Alfred Hospital, Commercial Melbourne 3004, Melbourne, Australia. J.Ray@alfred.org.au.ORCID http://orcid.org/0000-0003-4833-5507
Penelope Allen *Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Ann Bacsi *Integrated Specialist Medical Care, Sydney, Australia.
Julian J Bosco *Department of Allergy, asthma and clinical immunology, Alfred Hospital, Commercial Road 3004, Melbourne, Australia.
Luke Chen *Department of Neuroscience, Monash University, Vic, Melbourne, 3004, Australia.
Michael Eller *Department of Neurology, Monash Medical Centre, Vic, Melbourne, Australia.
Hock Kua *Department of Pathology, Monash Medical Centre, Vic, Melbourne, Australia.
Lyndell L Lim *Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Manjit S Matharu *University College London (UCL) Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, University College London, Gower Street WC1E 6BT, London, UK.
Mastura Monif *Department of Neuroscience, Monash University, Vic, Melbourne, 3004, Australia.
Martin Ruttledge *Consultant Neurologist & Headache Clinical Lead, Beaumont Hospital, Beaumont Road, Dublin, Ireland.
Richard J Stark *Department of Neurology, Alfred Hospital, Commercial Melbourne 3004, Melbourne, Australia.
Elspeth J HuttonDepartment of Neurology, Alfred Hospital, Commercial Melbourne 3004, Melbourne, Australia.
The Alfred Hospital · AUMonash Medical Centre · AUThe University of Melbourne · AUBeaumont Hospital · IENational Hospital for Neurology and Neurosurgery · GBThe Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCalcitonin gene-related peptide (CGRP) is expressed throughout the body and is a known mediator of migraine, exerting this biological effect through activation of trigeminovascular, meningeal and associated neuronal pathways located in close proximity to the central nervous system. Monoclonal antibodies (mAb) targeting the CGRP pathway are an effective new preventive treatment for migraine, with a generally favourable adverse event profile. Pre-clinical evidence supports an anti-inflammatory/immunoregulatory role for CGRP in other organ systems, and therefore inhibition of the normal action of this peptide may promote a pro-inflammatory response. CASES: We present a case series of eight patients with new or significantly worsened inflammatory pathology in close temporal association with the commencement of CGRP mAb therapy.

conclusionThis case series provides novel insights on the potential molecular mechanisms and side-effects of CGRP antagonism in migraine and supports clinical vigilance in patient care going forward.

Indexed as

Calcitonin Gene-Related PeptideMigraine DisordersAntibodies, MonoclonalCalcitoninCentral Nervous SystemHumansAntibodies, MonoclonalCalcitoninCalcitonin Gene-Related PeptideAutoimmune diseasesCGRPCGRP receptor antagonistsDrug-related side effects and adverse reactionsMigraineMonoclonal antibodies

Identifiers

PMID34625019
PMCPMC8501661
OpenAlexW3203956598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.